A Study of LY3502970 in Healthy Male Participants

Sponsor
Eli Lilly and Company
Study ID
NCT04680767
Phase
PHASE1
Status
Completed

Conditions

  • Healthy

Eligibility Criteria

Sex
MALE
Age
35 Years - 55 Years
Healthy Volunteers
Accepted

Interventions

  • [¹⁴C]-LY3502970 — DRUG
    Administered orally.

Study Details

The main purpose of this study is to measure how much of the study drug gets into the bloodstream and how long it takes the body to eliminate it. This study will involve a single dose of ¹⁴C radiolabelled LY3502970. This means that a radioactive substance will be incorporated into the study drug. The purposes are to investigate the study drug and its breakdown products and to find out how much of these pass from blood into urine and feces. The study will last up to 8 weeks (maximum).

Key Dates

Start date
Mar 29, 2021
Status verified
Apr 2026
Primary completion
Jul 3, 2021
Completion
Jul 3, 2021

Study Design

Enrollment
6 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: 3mg [¹⁴C]-LY3502970
    Participants received a single oral dose of 3 milligrams (mg) of carbon-14-labeled \[¹⁴C\]-LY3502970, containing approximately 200 microcuries (µCi) of radioactivity on Day 1.

Primary Outcome Measure

Feces Excretion of LY3502970 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered [ Time Frame: 0, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, and 384 hours (h) postdose ]

Related coverage on Hipa.ai

Related Studies